The rising participation of women in the workforce has fueled the demand for breast milk substitutes (BMS). The International Labour Organization reported that in 2022, 47% of the global labor force was female, underscoring the prevalence of working mothers.
Due to time constraints and professional commitments, many mothers struggle to breastfeed, making BMS a viable alternative. This trend underscores the sustained demand for convenient feeding solutions like BMS among working mothers.
Economic advancements in developing areas, especially in the Asia-Pacific, Latin America, and certain African regions, have transitioned weaning practices from traditional methods to formula feeding. This evolution, spurred by rising disposable incomes and urbanization, has bolstered BMS product sales.
The World Bank highlighted a significant urban shift, noting that the urban populace in low- and middle-income nations surged from 35% in 2000 to 52% in 2020. Such urbanization dynamics are poised to further propel BMS adoption in these emerging markets.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
The breast milk substitutes industry was valued at approximately USD 87.4 billion in 2024 and is estimated to grow at a 9.9% CAGR from 2025 to 2034, driven by increasing maternal health challenges and insufficient milk supply.
The milk-based formula segment held the largest revenue share of 72.5% in 2024 due to health-related factors such as insufficient milk supply and the risk of disease transmission from mothers to infants.
The U.S. breast milk substitutes market is projected to reach USD 52.6 billion by 2034, driven by the high percentage of mothers returning to the workforce shortly after childbirth.
In 2023, 68.9% of mothers with children under 6 were part of the labor force, making breast milk substitutes a practical feeding option for working mothers.
Key players in the market include Abbott Laboratories, Arla Foods, Beingmate Baby & Child Food, Danone, Fonterra Co-operative Group, FrieslandCampina, Hero Group, HiPP, Kendamil, and Mead Johnson.